Amgen Inc. Stock price

Equities

AMGN

US0311621009

Pharmaceuticals

Market Closed - Nasdaq 20:59:59 27/02/2024 GMT 5-day change 1st Jan Change
278.5 USD -2.76% Intraday chart for Amgen Inc. -1.77% -3.31%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
limited-time offer
Enjoy this offer
* See conditions on site
Sales 2024 * 32.88B 2,592B Sales 2025 * 34.06B 2,685B Capitalization 153B 12,099B
Net income 2024 * 6.19B 488B Net income 2025 * 7.43B 586B EV / Sales 2024 * 6.11 x
Net Debt 2024 * 47.48B 3,743B Net Debt 2025 * 42.05B 3,315B EV / Sales 2025 * 5.74 x
P/E ratio 2024 *
24.7 x
P/E ratio 2025 *
19.1 x
Employees 26,700
Yield 2024 *
3.23%
Yield 2025 *
3.5%
Free-Float 99.63%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Amgen Inc.

1 day-2.76%
1 week-1.77%
Current month-11.39%
1 month-11.16%
3 months+5.38%
6 months+8.55%
Current year-3.31%
More quotes
1 week
277.09
Extreme 277.09
292.24
1 month
277.09
Extreme 277.09
329.72
Current year
277.09
Extreme 277.09
329.72
1 year
211.71
Extreme 211.71
329.72
3 years
198.64
Extreme 198.64
329.72
5 years
166.30
Extreme 166.3
329.72
10 years
108.20
Extreme 108.2
329.72
More quotes
Managers TitleAgeSince
Chief Executive Officer 61 31/05/06
Director of Finance/CFO 65 22/10/19
Chief Operating Officer 56 31/12/06
Members of the board TitleAgeSince
Director/Board Member 67 02/02/17
Director/Board Member 68 13/10/16
Director/Board Member 75 16/10/14
More insiders
Date Price Change Volume
26/02/24 286.4 -0.97% 2,448,935
23/02/24 289.2 +1.40% 2,462,555
22/02/24 285.2 +0.61% 2,992,891
21/02/24 283.5 -0.02% 1,934,490

Delayed Quote Nasdaq, February 27, 2024 at 08:59 pm

More quotes
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows: - drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.; - other (5.8%): primarily royalties. The United States account for 70.6% of net sales.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
27
Last Close Price
286.4 USD
Average target price
303.6 USD
Spread / Average Target
+6.03%
Consensus
  1. Stock
  2. Equities
  3. Stock Amgen Inc. - Nasdaq
-40% Limited-time offer: Our subscriptions help you unlock the best investment opportunities.
SIGN UP NOW